Gastrointestinal Bleeding Treatment Market Analysis

Gastrointestinal Bleeding Treatment Market Analysis

To get key market trends

  Download Free Sample

Based on product, the market is segmented into endoscopic hemostatic devices, closure devices, and other products. The endoscopic hemostatic devices segment is further divided into endoscopic mechanical devices and endoscopic thermal devices. The endoscopic hemostatic devices segment dominated the market with revenue of USD 498.8 million in 2023.
 

• Endoscopic hemostatic devices are widely used due to their high efficacy and minimally invasive nature. These devices are favored for their ability to achieve hemostasis quickly and effectively, reducing the need for more invasive surgical interventions.
   
• These devices offer precise control and easy application, making them preferred options for both acute and chronic bleeding cases.
   
• Moreover, advancements in endoscopic technology, including improved device designs and better visualization capabilities, enhance the efficacy and safety of these devices, further boosting their market share.
   

Based on GI tract division, the gastrointestinal bleeding treatment market is segmented into upper GI tract and lower GI tract. The upper GI tract segment held a dominant market share of 72.4% in 2023.
 

• Higher market share of upper GI tract bleeding can be attributed to the high incidence of peptic ulcers that develop in the stomach or the upper part of the small intestine (duodenum).
   
• Additionally, rising cases of gastritis, esophagitis, Mallory-Weiss tears (tears in the mucous membrane at the junction of the esophagus and stomach), and certain cancers contribute to upper GI bleeding, further enhancing the segment expansion.
   

Based on onset, the gastrointestinal bleeding treatment market is classified into acute and chronic. The acute segment is expected to reach USD 1.1 billion by 2032.
 

• Acute GI tract bleeding, characterized by the sudden onset of bleeding in the GI tract, often requires immediate medical attention and intervention.
   
• Additionally, the rising prevalence of risk factors such as NSAID use, alcohol consumption, and Helicobacter pylori infection has led to a higher incidence of acute GI bleeding cases.
   
• Furthermore, the availability of innovative hemostatic agents and the growing adoption of minimally invasive surgical procedures have further expanded the market for acute GI bleeding treatments.
   

Based on end-use, the gastrointestinal bleeding treatment market is classified into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment dominated the market in 2023 and is anticipated to grow at 7.8% CAGR between 2024- 2032.
 

• The hospitals segment holds a substantial share in the market, driven by its pivotal role as a primary healthcare provider for acute and chronic conditions.
   
• Hospitals offer a comprehensive range of treatment options, including endoscopic interventions and surgical procedures, making them a prominent end-user of GI tract bleeding treatments.
   
• Further, their advanced infrastructure, specialized medical staff, and access to cutting-edge technologies contribute significantly to their dominance in the market.
   
• Additionally, hospitals often serve as referral centers for complex cases, further solidifying their position in the gastrointestinal bleeding treatment landscape.
   

In 2023, North America held a market share of 41.6% in the global gastrointestinal bleeding treatment market and is expected to reach USD 635.7 million by 2032.
 

• High regional growth can be attributed to the high prevalence of gastrointestinal disorders in the region. For instance, as per the CDC, peptic ulcer is a common illness in the U.S. affecting over 6 million persons each year.
   
• Additionally, well-established healthcare infrastructure, increasing adoption of advanced treatment options, strong presence of key market players, coupled with extensive research and development activities, further contribute to its dominant market position.
   
• Moreover, favorable reimbursement policies and increasing healthcare expenditure supports the growth of the market in North America.